Our Paris Life Sciences team advised Hepta Medical, a medical device company developing thermal ablation therapy for early-stage lung cancer, on its €5.7 million Series A financing round.
This round was led by Bpifrance and included M&L Healthcare and Clery IG.
Hepta Medical was founded in 2019 out of MD Start – the medical device incubator backed by Sofinnova Partners. The funds raised will enable HEPTA to initiate the US regulatory approval process for the first version of the device and to commence its clinical trials.
The Goodwin team was led by Xavier Leroux and included Julie Messerig on corporate aspects.